APA (7th ed.) Citation

Bessonova, T. O., Mukhortova, P. A., Teryan, R. A., Bagdasarov, A. D., & Musina, N. Z. Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program. IRBIS LLC.

Chicago Style (17th ed.) Citation

Bessonova, T. O., P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, and N. Z. Musina. Cost-effectiveness Analysis of Using Atorvastatin, Simvastatin, Ezetimibe, Alirocumab, Evolocumab, Inclisiran in Adults with Very High Cardiovascular Risk Under the Preferential Drug Provision Program. IRBIS LLC.

MLA (9th ed.) Citation

Bessonova, T. O., et al. Cost-effectiveness Analysis of Using Atorvastatin, Simvastatin, Ezetimibe, Alirocumab, Evolocumab, Inclisiran in Adults with Very High Cardiovascular Risk Under the Preferential Drug Provision Program. IRBIS LLC.